Alexandra Gerlach, Associate Editor

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

Moderate to severe obstructive sleep apnea significantly increases the risk of cerebral microbleeds.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Low-dose aspirin significantly reduces heart attack, stroke, and death risks in adults with type 2 diabetes and elevated cardiovascular risk.

Experts analyze the effects of MFN tariffs and DTC channels on drug pricing, patient access, and pharmacy operations, revealing critical industry insights.

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

Maternal COVID-19 infection raises concerns about neurodevelopmental disorders in children, emphasizing the need for effective fever and infection management during pregnancy.

Long-term melatonin use for insomnia raises heart failure risks, highlighting the need for careful evaluation of sleep aids and underlying health issues.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Teva Pharmaceuticals recalls over 580,000 bottles of prazosin due to contamination concerns, urging patients to consult healthcare providers.

A groundbreaking vaccine shows 73% efficacy against Salmonella Paratyphi A, offering hope in combating enteric fever globally.

Research reveals a notable risk of invasive fungal infections in multiple myeloma patients undergoing BCMA-targeted CAR T-cell therapy, highlighting the need for vigilant monitoring.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.

Adjuvant abemaciclib plus endocrine therapy significantly enhances overall survival in high-risk HR-positive HER2-negative breast cancer.

Durvalumab combined with FLOT shows significant survival benefits for patients with resectable gastroesophageal junction cancer, regardless of PD-L1 status.

Nivolumab plus chemotherapy and ipilimumab show significant long-term survival benefits for advanced esophageal squamous cell carcinoma.

Research reveals that statins and metformin enhance survival rates in early-stage triple-negative breast cancer, offering hope for affordable treatment options.

The move emphasizes the need for vigilant monitoring.

CDC layoffs threaten public health surveillance, prompting urgent reinstatement of staff as pharmacists face challenges in community health response.

Invasive lobular carcinoma poses unique detection and treatment challenges, highlighting the urgent need for targeted research and improved survival strategies.